These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23034140)

  • 21. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of analytic methods for biomarkers used in drug development.
    Chau CH; Rixe O; McLeod H; Figg WD
    Clin Cancer Res; 2008 Oct; 14(19):5967-76. PubMed ID: 18829475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.
    Poste G; Carbone DP; Parkinson DR; Verweij J; Hewitt SM; Jessup JM
    Clin Cancer Res; 2012 Mar; 18(6):1515-23. PubMed ID: 22422403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic biomarkers in the development of stratified cancer medicine.
    Figg WD; Newell DR
    Clin Cancer Res; 2014 May; 20(10):2525-9. PubMed ID: 24831275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
    Fridlyand J; Simon RM; Walrath JC; Roach N; Buller R; Schenkein DP; Flaherty KT; Allen JD; Sigal EV; Scher HI
    Nat Rev Drug Discov; 2013 Oct; 12(10):743-55. PubMed ID: 24008432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamic biomarkers in model-based drug development in oncology.
    Keizer RJ; Schellens JH; Beijnen JH; Huitema AD
    Curr Clin Pharmacol; 2011 Feb; 6(1):30-40. PubMed ID: 21235464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer biomarkers: current issues and future directions.
    Jain KK
    Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
    de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
    Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.
    Bullock JM; Lin T; Bilic S
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S105-S115. PubMed ID: 28921642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.
    Wilson JL; Altman RB
    Exp Biol Med (Maywood); 2018 Feb; 243(3):313-322. PubMed ID: 29199461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular pathology as the driving force for personalized oncology.
    Oktay MH; Hui P
    Expert Rev Mol Diagn; 2012 Nov; 12(8):811-3. PubMed ID: 23249199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.
    Doble B; Tan M; Harris A; Lorgelly P
    Expert Rev Mol Diagn; 2015 Feb; 15(2):235-54. PubMed ID: 25142227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
    Collins DC; Sundar R; Lim JSJ; Yap TA
    Trends Pharmacol Sci; 2017 Jan; 38(1):25-40. PubMed ID: 27871777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions?
    Sargent D
    Oncologist; 2010; 15 Suppl 1():19-23. PubMed ID: 20237213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational research in phase I trials.
    Fasolo A; Sessa C
    Clin Transl Oncol; 2009 Sep; 11(9):580-8. PubMed ID: 19775997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biomarker strategy for cancer treatment and cancer drug development].
    Koizumi F
    Nihon Yakurigaku Zasshi; 2008 Aug; 132(2):105-10. PubMed ID: 18689960
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.